Lyell Immunopharma Inc. (LYEL)
NASDAQ: LYEL
· Real-Time Price · USD
10.87
0.29 (2.74%)
At close: Aug 18, 2025, 3:59 PM
10.88
0.14%
After-hours: Aug 18, 2025, 04:10 PM EDT
2.74% (1D)
| Bid | 10.44 |
| Market Cap | 208.83M |
| Revenue (ttm) | 65K |
| Net Income (ttm) | -334.52M |
| EPS (ttm) | -24.26 |
| PE Ratio (ttm) | -0.45 |
| Forward PE | -0.76 |
| Analyst | Hold |
| Ask | 11.2 |
| Volume | 21,056 |
| Avg. Volume (20D) | 143,721 |
| Open | 10.60 |
| Previous Close | 10.58 |
| Day's Range | 10.49 - 11.04 |
| 52-Week Range | 7.65 - 32.40 |
| Beta | -0.20 |
About LYEL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LYEL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LYEL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+19.31%
Lyell Immunopharma shares are trading higher after...
Unlock content with
Pro Subscription
9 months ago
+19.35%
Lyell Immunopharma shares are trading higher. The stock may be moving on continued strength after the company announced yesterday it will present clinical data from its Phase 1-2 trial of IMPT-314 CAR T-cell therapy for B-cell lymphoma at ASH 2024.
